Study identifier:D2710C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A randomized, blind, placebo-controlled, single-centre phase I study in healthy volunteers to assess the safety, tolerability and pharmacokinetics of AZD7687 after single ascending oral doses
Healthy
Phase 1
Yes
AZD7687, Placebo
Male
64
Interventional
20 Years - 45 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Other
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Active AZD7687 oral suspension | Drug: AZD7687 Single oral dose |
Experimental: Placebo placebo oral suspension | Drug: Placebo Single oral dose |